Blueprint Medicines stock was soaring Monday after French drugmaker Sanofi said it had agreed to buy the biotech company for ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...